UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~September 8~~ November 5, 2025

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	~~001-39218~~	~~16-0977505~~	001-39218	16-0977505
(State or other jurisdiction of	(Commission File Number)	(I.R.S. Employer
(State or other jurisdiction of incorporation or organization)			(Commission File Number)	(I.R.S. EmployerIdentification No.)
incorporation or organization)		Identification No.)

11311 Concept Blvd
11311 Concept BlvdLargo, FL		33773
Largo, Florida	33773
(Address of principal executive offices)		(Zip code)
(Address of principal executive offices)	(Zip code)

(727) 392-6464

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act

Title of each class	~~Trading Symbol(s)~~	~~Name of each exchange on which registered~~	Trading Symbol			Name of each exchange on which registered
Common Stock, $0.01 par value	~~CNMD~~	~~NYSE~~	CNMD			NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 Results ~~Departure~~ of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Condition

On ~~September 8~~November 5, 2025, ~~the Board of Directors (the “Board”) of~~ CONMED Corporation ~~(the~~issued ~~“Company”) appointed Kim Kelderman as~~ a ~~director~~press ~~effective~~release ~~immediately.~~announcing ~~Mr.~~financial ~~Kelderman~~results ~~was~~for ~~appointed to~~ the ~~Corporate~~third ~~Governance~~quarter ~~and~~ended ~~Nominating~~September 30, ~~Committee and the Strategy Committee~~2025. ~~The~~A ~~Board~~copy ~~determined~~of ~~that~~this ~~Mr.~~press ~~Kelderman~~release is ~~independent and~~attached ~~meets~~hereto ~~the applicable director independence requirements of the New York Stock Exchange and the Company’s director independence standards,~~ as ~~adopted~~Exhibit ~~by the Board~~99.1.

~~Mr.~~The ~~Kelderman~~information ~~has~~in ~~been~~this ~~President,~~Current ~~Chief~~Report ~~Executive~~on ~~Officer,~~Form ~~and member of the Board of Bio~~8-~~Techne~~K ~~(NASDAQ:~~that ~~TECH)~~is ~~since~~furnished ~~February~~under ~~2024,~~“Item ~~having~~2.02. ~~joined~~Results ~~Bio-Techne~~of inOperations ~~April~~and ~~2018,~~Financial asCondition” ~~President, Diagnostics~~ and ~~Genomics, and~~Exhibit ~~having served as Chief Operating Officer from November 2023 to January 2024~~99.1 ~~Prior~~attached tohereto ~~Bio-Techne,~~shall ~~Mr.~~not ~~Kelderman~~be ~~was~~deemed ~~employed~~“filed” atfor ~~Thermo Fisher~~purposes ~~Scientific~~of ~~where~~Section he18 ~~led three different businesses~~ of ~~increasing scale and complexity. Mr. Kelderman managed~~ the ~~Platforms~~Securities ~~and Content~~Act of ~~the Genetic Sciences Division~~1934, ~~where~~nor heshall ~~was~~they ~~responsible~~be ~~for~~deemed ~~the~~incorporated ~~Instrumentation,~~by ~~Software,~~reference ~~Consumables~~in ~~and~~any ~~Assays~~filing ~~businesses, and~~under ~~brands~~the ~~such~~Securities asAct ~~Applied~~of ~~Biosystems and legacy Affymetrix. Before joining Thermo Fisher~~1933, ~~Mr.~~except ~~Kelderman served~~ as ~~Senior~~shall ~~Segment~~be ~~Leader at~~expressly ~~Becton~~set ~~Dickinson,~~forth ~~managing~~by ~~the~~specific ~~global~~reference ~~Blood Tubes "Vacutainer" business. Mr. Kelderman holds a Bachelor of Science degree from Hogeschool Heerlen of Applied Sciences~~ in ~~the~~such ~~Netherlands~~filing.

There are no understandings or arrangements between Mr. Kelderman or any third parties pursuant to which he was selected as a director. There are no related party transactions that would be required to be disclosed under Item 404(a) of Reg S-K with respect to Mr. Kelderman. In addition, Mr. Kelderman does not have any familial relationship with any director or executive officer of the Company.

As a non-employee director, Mr. Kelderman will receive the annual cash and equity compensation received by each of the Company’s non-employee directors, as further described in the Company’s proxy statement dated April 8, 2025. The Board granted Mr. Kelderman a prorated portion of the annual equity compensation granted to directors with a value of approximately $134,766, based on a Black Scholes valuation, which grant was comprised of 500 restricted stock units and stock options to acquire 6,227 shares of the Company’s common stock with an exercise price equal to the closing price of the Company’s stock on September 8, 2025. The awards will vest in full on September 8, 2026.

A copy of a press release issued on September 9, 2025, announcing Mr. Kelderman’s election and describing his background and qualifications is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are included herewith:

Exhibit No.	~~Exhibit No.~~	~~Description of Exhibit~~	Description of Exhibit
99.1	~~99.1~~	~~Press release dated September 9, 2025, issued by CONMED Corporation.~~	Press release dated November 5, 2025, issued by CONMED Corporation.
104	~~104~~	~~Cover Page Interactive Data File (embedded within the Inline XBRL Document).~~	Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 9, 2025	CONMED CORPORATION
	(Registrant)
	By:	/s/ Todd W. Garner
	Name:	Todd W. Garner
	Title:	Executive Vice President, Finance &
		Chief Financial Officer


Date: November 5, 2025			CONMED CORPORATION
			(Registrant)


By:			/s/ Todd W. Garner
Name:			Todd W. Garner
Title:			Executive Vice President, Finance & Chief Financial Officer

Filing Compare · CONMED Corp